Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The impact of environmental mycobiomes on geographic variation in COVID-19 mortality

Joshua Ladau, Katrina Abuabara, Angelica M. Walker, Marcin P. Joachimiak, Ishan Bansal, Yulun Wu, Elijah B. Hoffman, Chaincy Kuo, Nicola Falco, Jared Streich, Mark J. van der Laan, Haruko M. Wainwright, Eoin L. Brodie, Matthias Hess, Daniel Jacobson, James B. Brown
doi: https://doi.org/10.1101/2021.12.14.21267549
Joshua Ladau
1Computational Biosciences Group, Lawrence Berkeley National Laboratory, Berkeley, CA, USA 94720
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jladau@gmail.com
Katrina Abuabara
2Division of Epidemiology and Biostatistics, University of California, Berkeley, CA 94720
3Department of Dermatology, University of California, San Francisco, CA 94115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelica M. Walker
4Bredesen Center for Interdisciplinary Research and Graduate Education, University of Tennessee Knoxville, Knoxville, TN 37996
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcin P. Joachimiak
5Biosystems Data Science, EGSB, Lawrence Berkeley National Laboratory, 1 Cyclotron Rd., M/S 74-316C, Berkeley, CA 94720
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ishan Bansal
1Computational Biosciences Group, Lawrence Berkeley National Laboratory, Berkeley, CA, USA 94720
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yulun Wu
6Graduate Group in Biostatistics, University of California, Berkeley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elijah B. Hoffman
6Graduate Group in Biostatistics, University of California, Berkeley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chaincy Kuo
7Earth and Environmental Sciences Area, Lawrence Berkeley National Laboratory, 1 Cyclotron Rd., M/S 74-316C, Berkeley, CA 94720
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Falco
7Earth and Environmental Sciences Area, Lawrence Berkeley National Laboratory, 1 Cyclotron Rd., M/S 74-316C, Berkeley, CA 94720
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jared Streich
8Biosciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. van der Laan
6Graduate Group in Biostatistics, University of California, Berkeley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haruko M. Wainwright
7Earth and Environmental Sciences Area, Lawrence Berkeley National Laboratory, 1 Cyclotron Rd., M/S 74-316C, Berkeley, CA 94720
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eoin L. Brodie
7Earth and Environmental Sciences Area, Lawrence Berkeley National Laboratory, 1 Cyclotron Rd., M/S 74-316C, Berkeley, CA 94720
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Hess
9University of California, Davis, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Jacobson
8Biosciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James B. Brown
1Computational Biosciences Group, Lawrence Berkeley National Laboratory, Berkeley, CA, USA 94720
10Statistics Department, University of California, Berkeley, CA, USA 94720
11Arva Intelligence, Inc., Salt Lake City, UT. 84101
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Mortality rates during the COVID-19 pandemic have varied by orders of magnitude across communities in the United States1. Individual, socioeconomic, and environmental factors have been linked to health outcomes of COVID-192,3,4,5. It is now widely appreciated that the environmental microbiome, composed of microbial communities associated with soil, water, atmosphere, and the built environment, impacts immune system development and susceptibility to immune-mediated disease6,7,8. The human microbiome has been linked to individual COVID-19 disease outcomes9, but there are limited data on the influence of the environmental microbiome on geographic variation in COVID-19 across populations10. To fill this knowledge gap, we used taxonomic profiles of fungal communities associated with 1,135 homes in 494 counties from across the United States in a machine learning analysis to predict COVID-19 Infection Fatality Ratios (the number of deaths caused by COVID-19 per 1000 SARS-CoV-2 infections1; ‘IFR’). Here we show that increased fungal diversity, and in particular indoor exposure to outdoor fungi, is associated with reduced SARS-CoV-2 IFR. Further, we identify seven fungal genera that are the predominant drivers of this protective signal and may play a role in suppressing COVID-19 mortality. This relationship is strongest in counties where human populations have remained stable over at least the previous decade, consistent with the importance of early-life microbial exposures11. We also assessed the explanatory power of 754 other environmental and socioeconomic factors, and found that indoor-outdoor fungal beta-diversity is amongst the strongest predictors of county-level IFR, on par with the most important known COVID-19 risk factors, including age12. We anticipate that our study will be a starting point for further integration of environmental mycobiome data with population health information, providing an important missing link in our capacity to identify vulnerable populations. Ultimately, our identification of specific genera predicted to be protective against COVID-19 mortality may point toward novel, proactive therapeutic approaches to infectious disease.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This manuscript has been coauthored by UT-Battelle, LLC under contract no. DE-AC05-00OR22725 with the U.S. Department of Energy. The United States Government retains and the publisher, by accepting the article for publication, acknowledges that the United States Government retains a nonexclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The Department of Energy will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan (http://energy.gov/downloads/doe-public-access-plan, last accessed September 16, 2020). Work at Oak Ridge and Lawrence Berkeley National Laboratories was supported by the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act, and was facilitated by previous breakthroughs obtained through the Laboratory Directed Research and Development Program of Lawrence Berkeley National Laboratory. M.P.J. was supported by a grant from the Laboratory Directed Research and Development (LDRD) Program of Lawrence Berkeley National Laboratory under U.S. Department of Energy Contract No. DE-AC02-05CH11231. Chris Mungall and Mark Miller (Lawrence Berkeley National Laboratory) assisted with mapping of Disbiome disease data to the Mondo ontology.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study involves only openly available human data, which can be obtained from: https://coronavirus.jhu.edu/ https://github.com/CSSEGISandData/COVID-19 https://covidtracking.com/

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

https://github.com/jladau/Covid19FungiSupplementaryTables

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 16, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The impact of environmental mycobiomes on geographic variation in COVID-19 mortality
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The impact of environmental mycobiomes on geographic variation in COVID-19 mortality
Joshua Ladau, Katrina Abuabara, Angelica M. Walker, Marcin P. Joachimiak, Ishan Bansal, Yulun Wu, Elijah B. Hoffman, Chaincy Kuo, Nicola Falco, Jared Streich, Mark J. van der Laan, Haruko M. Wainwright, Eoin L. Brodie, Matthias Hess, Daniel Jacobson, James B. Brown
medRxiv 2021.12.14.21267549; doi: https://doi.org/10.1101/2021.12.14.21267549
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The impact of environmental mycobiomes on geographic variation in COVID-19 mortality
Joshua Ladau, Katrina Abuabara, Angelica M. Walker, Marcin P. Joachimiak, Ishan Bansal, Yulun Wu, Elijah B. Hoffman, Chaincy Kuo, Nicola Falco, Jared Streich, Mark J. van der Laan, Haruko M. Wainwright, Eoin L. Brodie, Matthias Hess, Daniel Jacobson, James B. Brown
medRxiv 2021.12.14.21267549; doi: https://doi.org/10.1101/2021.12.14.21267549

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1097)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9773)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2313)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1562)
  • Health Policy (736)
  • Health Systems and Quality Improvement (604)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11650)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1180)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4663)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)